Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414362 · ClinicalTrials.gov registry record
Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 1,000
- Enrollment target
NCT00414362: Completed study, sponsored by University of Pittsburgh.
NCT00414362 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00414362 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
The information collected will optimize the management of patients with urinary tract infections with secondary bacteremia, primarily with gram negative bacteria especially Escherichia coli. The current IDSA guideline endorses the use of fluoroquinolones and trimethoprim-sulfamethoxazole as the first line agents. However, over use of this empiric regimen could result in in appropriate treatment of bacteremia.
Primary Outcome
health status
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2007-02 |
| Est. Completion | 2017-06 |
What the finished NCT00414362 record still lists
NCT00414362 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00414362 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00414362 about?
NCT00414362 is a clinical study titled "Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin". The information collected will optimize the management of patients with urinary tract infections with secondary bacteremia, primarily with gram negative bacteria especially Escherichia coli. The current IDSA guideline endorses the use of fluoroquinolones and trimethoprim-sulfamethoxazole as the firs...
What is the current status of trial NCT00414362?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2007-02. Estimated completion is 2017-06.
Who is sponsoring clinical trial NCT00414362?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia